Search

Editors

Richard L. Cassin Publisher and Editor

Andy Spalding Senior Editor

Jessica Tillipman Senior Editor

Elizabeth K. Spahn Editor Emeritus

Cody Worthington Contributing Editor

Julie DiMauro Contributing Editor

Thomas Fox Contributing Editor

Marc Alain Bohn Contributing Editor

Bill Waite Contributing Editor

Shruti J. Shah Contributing Editor

Russell A. Stamets Contributing Editor

Richard Bistrong Contributing Editor 

Eric Carlson Contributing Editor

Bill Steinman Contributing Editor

Aarti Maharaj Contributing Editor


FCPA Blog Daily News

Entries in GSK (13)

Monday
Oct022017

Federal judge tosses China investigators’ RICO claims against GSK

A federal judge in Philadelphia Friday dismissed a civil complaint against UK-based GlaxoSmithKline brought by a British private investigator and his American wife and their China-based company.

Click to read more ...

Thursday
Apr202017

Elizabeth David-Barrett: Pharmas and the repeated failure of anti-bribery compliance

Pharmaceuticals companies continue to fall foul of the FCPA and other anti-bribery laws, with a number of 2016 cases suggesting a vulnerability around marketing practices especially in the Asia-Pacific region. Why does a sector that is way ahead of the compliance game in so many ways keep getting caught out by anti-bribery laws?

Click to read more ...

Thursday
Feb232017

Tom Fox: Compliance in the Age of Mercantilism

What does the failure of the Kraft Heinz attempted hostile takeover of Unilever portend for the greater world of global anti-corruption enforcement specifically and compliance programs more generally?

Click to read more ...

Wednesday
Jan042017

Compliance Alert: Speaker fees are often toxic

Last month Forest Labs paid $38 million to settle allegations it paid doctors speaker fees for sometimes phony events so they would prescribe its drugs. It was the latest in a string of "speaker fee" cases.

Click to read more ...

Friday
Sep302016

GSK pays SEC $20 million to settle China FCPA violations

The Securities and Exchange Commission said Friday UK-based pharma GlaxoSmithKline plc will pay a $20 million civil penalty to settle charges that it violated the Foreign Corrupt Practices Act when China-based subsidiaries spent millions of dollars on pay-to-prescribe schemes for several years to pump up sales.

Click to read more ...

Tuesday
Nov252014

SFO Director Green: ‘There are plenty of foxes for the hounds to chase down’

Image courtesy of the SFOAt Pinsent Masons regulatory conference in London a few weeks ago, David Green, the chief of the UK Serious Fraud Office, talked about how many known frauds happen on his turf. Here's a hint: Lock up the silverware because it's a growth industry.

Click to read more ...

Tuesday
Oct282014

Collective Action: A new approach to combat corruption (Part 7)

In my prior post on Collective Action, I wrote about the importance of voluntary codes of conduct and concluded that in an era of weak regulation, corporate behaviour would have been significantly worse over the last decades without them.

Click to read more ...

Wednesday
Jun042014

Job: Regional Specialist, Anti-Bribery & Corruption (GSK Singapore)

Job Title: Regional Specialist, Anti-Bribery & Corruption

Employer: GlaxoSmithKline

Location: Singapore

Click to read more ...

Wednesday
May142014

Chinese police charge former GSK China chief Mark Reilly

Chinese police Wednesday charged the British former boss of GlaxoSmithKline's China unit and two other company executives with corruption for bribing health officials and doctors.

Click to read more ...

Friday
Apr182014

GSK confirms Jordan, Lebanon bribe probes

GlaxoSmithKline said it is investigating allegations of bribery in Jordan and Lebanon first reported by the media.

Click to read more ...

Tuesday
Apr082014

GSK probes Iraq sales

British pharma GlaxoSmithKline said it is investigating allegations the company hired government-employed doctors and pharmacists in Iraq as paid sales reps for its products.

Click to read more ...

Thursday
Dec192013

Bravery ‘over there’ is the big story of 2013

We Americans sometimes think that because we have the FCPA and activist enforcement agencies, we also have a monopoly on the fight against corruption. Not true. There are people all over the world standing firm against graft. No matter where, it's dangerous work. But there was plenty of courage and persistence on display in 2013 beyond our borders.

Click to read more ...